Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

January 30, 2025

Conditions
Parkinson's Disease
Interventions
DRUG

Apomorphine

Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour

OTHER

Best Medical Treatment

Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies

Trial Locations (20)

13385

APHM, hospital of Timone, Marseille

14033

Caen University Hospital, Caen

30029

Caremeau University Hospital, Nîmes

31059

Purpan University Hospital, Toulouse

33000

Pellegrin University Hospital, Bordeaux

34070

Clinique Beau-Soleil, Montpellier

34295

Montpellier University Hospital, Montpellier

35033

Rennes University Hospital, Rennes

42055

Saint-Etienne University Hospital, Saint-Etienne

44093

Laennec Hospital, Nantes

54035

Nancy University Hospital, Nancy

59037

Lille University Hospital, Lille

63003

Clermont-Ferrand University Hospital, Clermont-Ferrand

64109

Bayonne Côte Basque Hospital, Bayonne

67098

Hautepierre University Hospital, Strasbourg

69677

Pierre Wertheimer Hospital, Bron

75651

Pitié-Salpêtriere Hospital, Paris

80054

Amiens University Hospital, Amiens

86021

Poitiers University Hospital, Poitiers

06002

Pasteur 2 University Hospital, Nice

All Listed Sponsors
lead

Rennes University Hospital

OTHER